^
Association details:
| Biomarker: | NCOA4-RET fusion |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MON-453 Dramatic Clinical Response to Lenvatinib in a Pediatric Patient with Advanced Metastatic Papillary Thyroid Carcinoma
Published date:
05/08/2020
Excerpt:
A 10-year-old female patient with locally advanced PTC...Histopathology confirmed the presence of a PTC (diffuse sclerosing variant) with a RET-PTC3 oncogene rearrangement. The patient was started on oral lenvatinib at a dose of 14 mg daily (14 mg/m/day). After 4 months on Lenvatinib, imaging studies showed a stable thyroid mass while the pulmonary nodules appeared stable to slightly smaller without evidence of new or progressive disease.
DOI:
10.1210/jendso/bvaa046.121
